USPTO Examiner HUANG GIGI GEORGIANA - Art Unit 1613

Recent Applications

Detailed information about the 100 most recent patent applications.

Application NumberTitleFiling DateDisposal DateDispositionTime (months)Office ActionsRestrictionsInterviewAppeal
18594725MODULATORS OF TNF-ALPHA ACTIVITYMarch 2024February 2025Allow1100YesNo
18441930ALLERGEN DESENSITIZATION METHODFebruary 2024May 2025Allow1510YesNo
18535520DEGRADANT COMPOUND IN A MEDICAMENTDecember 2023December 2024Abandon1211NoNo
18531082FORMULATIONS COMPRISING CARBACHOL AND BRIMONIDINE TO ENHANCE ANTI-PRESBYOPIA EFFECTSDecember 2023February 2025Allow1511YesNo
18500416OCULAR FORMULATIONS FOR DRUG-DELIVERY AND PROTECTION OF THE ANTERIOR SEGMENT OF THE EYENovember 2023April 2025Abandon1710NoNo
18494341KETOROLAC TROMETHAMINE COMPOSITIONS FOR TREATING OR PREVENTING OCULAR PAINOctober 2023April 2025Abandon1710NoNo
18471977MODULATORS OF TNF-ALPHA ACTIVITYSeptember 2023January 2024Allow401YesNo
18144771BROMODOMAIN INHIBITORMay 2023March 2025Abandon2201NoNo
18250921DEGRADANT COMPOUND IN A MEDICAMENTApril 2023June 2025Abandon2611NoNo
18134875USE OF SGC ACTIVATORS FOR THE TREATMENT OF OPHTHALMOLOGIC DISEASESApril 2023February 2025Abandon2221NoNo
18167783PHARMACEUTICAL COMPOSITIONS OF D10-DOCOSAHEXAENOIC ACID OR ESTERS THEREOFFebruary 2023April 2025Abandon2621NoYes
18154505OPHTHALMOLOGICALLY SUITABLE LOW PKA BUFFER-CONTAINING PILOCARPINE COMPOSITIONS AND RELATED METHODSJanuary 2023March 2025Abandon2631YesNo
17948376COMPOSITIONS, METHODS AND KITS FOR TREATING A CONTACT LENSSeptember 2022September 2024Allow2411YesNo
17902124METHODS AND COMPOSITIONS TO INHIBIT SYMPTOMS ASSOCIATED WITH VEISALGIASeptember 2022September 2024Abandon2411NoNo
17817729PHARMACEUTICAL FORMULATIONS FOR SUBCUTANEOUS ADMINISTRATION OF FUROSEMIDEAugust 2022March 2025Allow3221YesNo
178171361-METHYL-1H-PYRAZOL-3-YL DERIVATIVES FOR USE IN THE TREATMENT OF NEOVASCULAR DISEASESAugust 2022January 2024Allow1721YesNo
17813221KETOROLAC TROMETHAMINE COMPOSITIONS FOR TREATING OR PREVENTING OCULAR PAINJuly 2022December 2023Abandon1710NoNo
17736089METHODS FOR MODULATING CONDITIONS OF THE EYE USING NOVEL LATANOPROST COMPOUND OPHTHALMIC COMPOSITIONSMay 2022April 2024Abandon2331NoNo
17736080STABLE LATANOPROST COMPOUND OPHTHALMIC COMPOSITIONSMay 2022February 2024Abandon2231NoNo
17723079NICLOSAMIDE FORMULATIONS FOR TREATING DISEASEApril 2022December 2023Abandon1910NoNo
17695410ORAL PHARMACEUTICAL COMPOSITION COMPRISING ZONISAMIDE AND PROCESS OF PREPARATION THEREOFMarch 2022August 2022Allow501YesNo
17667418USE OF SGC ACTIVATORS FOR THE TREATMENT OF OPHTHALMOLOGIC DISEASESFebruary 2022June 2025Abandon4011NoNo
17562487EXTENDED RELEASE PHARMACEUTICAL COMPOSITIONS OF RIOCIGUATDecember 2021March 2023Abandon1411NoNo
17547028LIQUID DEPOT FOR NON-INVASIVE SUSTAINED DELIVERY OF AGENTS TO THE EYEDecember 2021March 2025Allow3941YesNo
17523648ALLERGEN DESENSITIZATION METHODNovember 2021November 2023Allow2411YesNo
17509774EMULSION FORMULATIONS OF MULTIKINASE INHIBITORSOctober 2021February 2023Allow1521YesNo
17494635SAFE BRINZOLAMIDE AND BRIMONIDINE COMPOSITIONS WITH ENHANCED BENZALKONIUM CHLORIDE CONTENTOctober 2021March 2023Abandon1821NoNo
17494713SAFE USE OF BRINZOLAMIDE AND BRIMONIDINE COMPOSITIONS WITH ENHANCED BENZALKONIUM CHLORIDE CONTENTOctober 2021May 2023Abandon1930YesNo
17352698COMPOSITIONS AND METHODS FOR TREATING OCULAR EDEMA, NEOVASCULARIZATION AND RELATED DISEASESJune 2021September 2024Abandon3921NoNo
17330067NICLOSAMIDE FORMULATIONS FOR TREATING DISEASEMay 2021February 2022Allow911YesNo
17238045TARGETED ADMINISTRATION TO THE OROPHARYNX OF VISCOUS OR DRY POWDER FLUTICASONE PROPIONATE AND RELATED CORTICOSTEROIDS FOR THE TREATMENT OF EOSINOPHILIC ESOPHAGITIS (EoE)April 2021June 2025Abandon4901NoNo
17215856METHODS OF ACUTE RESTORATION OF VASCULAR COMPLIANCEMarch 2021November 2023Abandon3101NoNo
17205915OMEGA-3 PENTAENOIC ACID COMPOSITIONS AND METHODS OF USEMarch 2021April 2025Abandon4901NoNo
172747811-ISOPROPYL-3-METHYL-8-(PYRIDIN-3-YL)-1,3-DIHYDRO-2H-IMIDAZO[4,5-c]CINNOLIN-2-ONE AS SELECTIVE MODULATORS OF ATAXIA TELANGIECTASIA MUTATED (ATM) KINASE AND USES THEREOFMarch 2021October 2024Allow4401YesNo
17192379PROCESSES FOR MAKING CYCLIC LIPID IMPLANTS FOR INTRAOCULAR USEMarch 2021March 2024Abandon3611NoNo
17250756OPHTHALMIC COMPOSITIONS AND METHODS FOR THE TREATMENT OF EYE DISORDERS AND SKIN DISEASESMarch 2021February 2025Abandon4801NoNo
17180532PHARMACEUTICAL COMPOSITIONS OF ALPHA-2-ADRENERGIC RECEPTOR AGONISTS AND THEIR USE FOR IMPROVING VISIONFebruary 2021April 2024Abandon3801NoNo
17132246COMPOSITIONS FOR DELIVERY OF THERAPEUTICS INTO THE EYES AND METHODS FOR MAKING AND USING SAMEDecember 2020December 2024Abandon4801NoNo
17251322METHODS AND COMPOSITIONS FOR TREATING AND/OR PREVENTING THE PROGRESSION AND/OR ONSET OF AGE-RELATED NEURODEGENERATIONDecember 2020June 2024Abandon4301NoNo
17251559INHIBITORS OF EGFR AND METHODS OF USE THEREOFDecember 2020August 2024Allow4401YesNo
17097898NICLOSAMIDE FORMULATIONS FOR TREATING DISEASENovember 2020April 2021Allow501YesNo
17094986METHOD AND COMPOSITION FOR TREATING OCULAR HYPERTENSION AND GLAUCOMANovember 2020May 2024Abandon4220NoNo
17053428PROPHYLACTIC OR THERAPEUTIC AGENT FOR PROSTATE CANCERNovember 2020January 2025Abandon5120NoNo
17048586SYNTHESIS OF DENTIMOL, AN ANTIGLAUCOMA DRUGOctober 2020May 2024Abandon4301NoNo
17068954OCULAR FORMULATIONS FOR DRUG-DELIVERY AND PROTECTION OF THE ANTERIOR SEGMENT OF THE EYEOctober 2020January 2024Abandon3910NoNo
16998708METHODS OF TREATING EYE DISEASES ASSOCIATED WITH INFLAMMATION AND VASCULAR PROLIFERATIONAugust 2020December 2022Allow2710NoNo
16970292COMPOSITIONS FOR PREVENTING OR TREATING UVEITISAugust 2020November 2023Abandon3901NoNo
16937444ALLERGEN DESENSITIZATION METHODJuly 2020October 2021Allow1510NoNo
16960090METHOTREXATE OPHTHALMIC SOLUTIONJuly 2020August 2023Abandon3810NoNo
16907310USE OF EMODIN IN TREATING RETINAL ISCHEMIA OR A DISEASE, CONDITION, OR DISORDER ASSOCIATED WITH RETINAL ISCHEMIAJune 2020February 2024Abandon4321NoNo
16956033OMIDENEPAG COMBINATIONJune 2020March 2024Abandon4521NoNo
16892645COMPOSITIONS AND METHODS FOR NON-SURGICAL TREATMENT OF PTOSISJune 2020July 2023Abandon3820NoNo
16879484METHOD FOR INHIBITING OSTEOCLAST DEVELOPMENTMay 2020January 2023Allow3220NoNo
16870898BROMODOMAIN INHIBITORMay 2020February 2023Allow3331YesNo
16869541LIPOIC ACID FORMULATIONSMay 2020January 2023Abandon3301NoNo
16760663Pharmaceutical Compositions for Controlling and/or Reducing the Progression of MyopiaApril 2020May 2025Abandon6031NoNo
16863753Compositions and Methods for Treatment of Ocular DiseasesApril 2020February 2022Allow2221YesNo
16825898OPHTHALMIC FORMULATIONS AND USES THEREOFMarch 2020June 2023Allow3920YesNo
16806694KETOROLAC TROMETHAMINE COMPOSITIONS FOR TREATING OR PREVENTING OCULAR PAINMarch 2020September 2022Abandon3010NoNo
16641621OCULAR PHARMACEUTICAL COMPOSITIONSFebruary 2020July 2023Allow4121YesNo
16790035FORMULATION OF A RILUZOLE SOLUTION WITH BETA-CYCLODEXTRINSFebruary 2020October 2024Abandon5631NoYes
16701602OPHTHALMIC FORMULATION AND METHOD FOR AMELIORATING PRESBYOPIADecember 2019January 2024Abandon4941YesNo
16617173COMPOSITIONS AND METHODS FOR TREATING DRY EYE SYNDROME DELIVERING ANTIBIOTIC MACROLIDENovember 2019January 2024Abandon5041NoNo
16686934JANUS KINASE INHIBITORS FOR TREATMENT OF DRY EYE AND OTHER EYE RELATED DISEASESNovember 2019May 2021Abandon1810YesNo
16664179PHARMACOLOGY OF VISUAL CYCLE MODULATORSOctober 2019October 2022Abandon3620NoNo
16600732PROCESSES FOR MAKING CYCLIC LIPID IMPLANTS FOR INTRAOCULAR USEOctober 2019August 2021Abandon2211NoNo
16600553LUTEIN-CONTAINING OPHTHALMIC COMPOSITIONOctober 2019May 2022Allow3110YesNo
16577262COMPOSITIONS AND METHODS FOR NON-SURGICAL TREATMENT OF PTOSISSeptember 2019August 2020Allow1121YesNo
16573384Methods and Compositions to Inhibit Symptoms Associated with VeisalgiaSeptember 2019June 2022Allow3211YesNo
16513103COMPOSITIONS AND METHODS FOR TREATING OCULAR EDEMA, NEOVASCULARIZATION AND RELATED DISEASESJuly 2019August 2021Abandon2511NoNo
16476138OPHTHALMIC SOLUTION OF BIMATOPROSTJuly 2019September 2021Allow2621YesNo
16399313PHOTOSTABLE ANTIOXIDANT COSMETIC COMPOSITIONApril 2019March 2022Abandon3511NoNo
16395206ALLERGEN DESENSITIZATION METHODApril 2019April 2020Allow1210YesNo
16373893COMPOSITIONS AND METHODS FOR TREATING INFLAMMATORY CONDITIONSApril 2019August 2021Abandon2901NoNo
16335343PHOTOCHROMATIC MODULATION WITH FLUORESCEIN FOR THE TREATMENT OF PHOTO-OCULODYNIA AND BLEPHAROSPASMMarch 2019April 2022Allow3711YesNo
16334393DRUG DELIVERY SYSTEM FOR THE DELIVERY OF INTEGRASE INHIBITORSMarch 2019June 2022Abandon3821NoNo
16354764ORAL PHARMACEUTICAL COMPOSITION COMPRISING ZONISAMIDE AND PROCESS OF PREPARATION THEREOFMarch 2019September 2022Allow4221YesNo
16295085PHARMACEUTICAL FORMULATIONS FOR SUBCUTANEOUS ADMINISTRATION OF FUROSEMIDEMarch 2019April 2022Allow3821NoNo
16317101METHODS AND POLYMER COMPOSITIONS FOR TREATING RETINAL DETACHMENT AND OTHER OCULAR DISORDERSJanuary 2019March 2021Abandon2601NoNo
16240578METHODS FOR THE TREATMENT AND PREVENTION OF AGE-RELATED RETINAL DYSFUNCTIONJanuary 2019October 2020Abandon2201NoNo
16184834Sustained-Release Implants for Lowering Intraocular Pressure with Extended Duration of EffectNovember 2018June 2023Abandon5530NoYes
16183562OPHTHALMIC PREPARATIONSNovember 2018September 2021Allow3441YesNo
16183593OPHTHALMIC PREPARATIONSNovember 2018December 2021Allow3851YesNo
16181763OPHTHALMIC DEVICES FOR DELIVERY OF HYDROPHOBIC COMFORT AGENTSNovember 2018October 2020Allow2301YesNo
16096603Compositions, Methods and Kits for Treating a Contact LensOctober 2018August 2022Allow4531YesNo
16095593METHODS, COMPOSITIONS AND USES RELATING THERETOOctober 2018December 2021Allow3821YesNo
16089715STORAGE-STABLE OPHTHALMIC COMPOSITIONSeptember 2018December 2021Allow3841YesYes
15780828USE OF ENZYME-MODIFIED ISOQUERCITRINAugust 2018February 2021Abandon3211NoNo
16036919ALLERGEN DESENSITIZATION METHODJuly 2018December 2018Allow510NoNo
16010739METHOD AND COMPOSITION FOR TREATING OCULAR HYPERTENSION AND GLAUCOMAJune 2018August 2020Allow2620NoNo
15968358THERAPEUTIC REGIMEN AND METHODS FOR TREATING OR AMELIORATING VISUAL DISORDERS ASSOCIATED WITH AN ENDOGENOUS RETINOID DEFICIENCYMay 2018December 2020Abandon3111NoNo
15962545METHOD OF USING A COMPOSITION FOR ENHANCING NEWBORN INFANT COGNITIVE, BRAIN AND/OR CNS DEVELOPMENTApril 2018April 2020Allow2411YesNo
15877865PHARMACEUTICAL FORMULATIONS FOR SUBCUTANEOUS ADMINISTRATION OF FUROSEMIDEJanuary 2018February 2019Allow1210YesNo
15849557FORMULATIONS OF TOCOTRIENOL QUINONES FOR THE TREATMENT OF OPHTHALMIC DISEASESDecember 2017October 2018Abandon1001NoNo
15839784METHODS FOR THE TREATMENT AND PREVENTION OF AGE-RELATED RETINAL DYSFUNCTIONDecember 2017March 2019Abandon1511NoNo
15837325Compositions and Methods for Non-Surgical Treatment of PtosisDecember 2017October 2020Abandon3420NoNo
15579030MOSQUITO VECTOR CONTROL COMPOSITIONS, METHODS AND PRODUCTS UTILIZING SAMEDecember 2017August 2023Allow6021YesYes
15807282METHODS OF TREATING EYE DISEASES ASSOCIATED WITH INFLAMMATION AND VASCULAR PROLIFERATIONNovember 2017February 2020Allow2721NoNo
15807166METHODS OF TREATING EYE DISEASES ASSOCIATED WITH INFLAMMATION AND VASCULAR PROLIFERATIONNovember 2017June 2020Allow3231YesNo
15807235METHODS OF TREATING EYE DISEASES ASSOCIATED WITH INFLAMMATION AND VASCULAR PROLIFERATIONNovember 2017May 2020Abandon3021NoNo

Appeals Overview

This analysis examines appeal outcomes and the strategic value of filing appeals for examiner HUANG, GIGI GEORGIANA.

Patent Trial and Appeal Board (PTAB) Decisions

Total PTAB Decisions
12
Examiner Affirmed
10
(83.3%)
Examiner Reversed
2
(16.7%)
Reversal Percentile
26.2%
Lower than average

What This Means

With a 16.7% reversal rate, the PTAB affirms the examiner's rejections in the vast majority of cases. This reversal rate is below the USPTO average, indicating that appeals face more challenges here than typical.

Strategic Value of Filing an Appeal

Total Appeal Filings
32
Allowed After Appeal Filing
3
(9.4%)
Not Allowed After Appeal Filing
29
(90.6%)
Filing Benefit Percentile
10.8%
Lower than average

Understanding Appeal Filing Strategy

Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.

In this dataset, 9.4% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the bottom 25% across the USPTO, indicating that filing appeals is less effective here than in most other areas.

Strategic Recommendations

Appeals to PTAB face challenges. Ensure your case has strong merit before committing to full Board review.

Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.

Examiner HUANG, GIGI GEORGIANA - Prosecution Strategy Guide

Executive Summary

Examiner HUANG, GIGI GEORGIANA works in Art Unit 1613 and has examined 189 patent applications in our dataset. With an allowance rate of 39.2%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 38 months.

Allowance Patterns

Examiner HUANG, GIGI GEORGIANA's allowance rate of 39.2% places them in the 4% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.

Office Action Patterns

On average, applications examined by HUANG, GIGI GEORGIANA receive 2.80 office actions before reaching final disposition. This places the examiner in the 92% percentile for office actions issued. This examiner issues more office actions than most examiners, which may indicate thorough examination or difficulty in reaching agreement with applicants.

Prosecution Timeline

The median time to disposition (half-life) for applications examined by HUANG, GIGI GEORGIANA is 38 months. This places the examiner in the 11% percentile for prosecution speed. Applications take longer to reach final disposition with this examiner compared to most others.

Interview Effectiveness

Conducting an examiner interview provides a +60.2% benefit to allowance rate for applications examined by HUANG, GIGI GEORGIANA. This interview benefit is in the 97% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.

Request for Continued Examination (RCE) Effectiveness

When applicants file an RCE with this examiner, 10.9% of applications are subsequently allowed. This success rate is in the 2% percentile among all examiners. Strategic Insight: RCEs show lower effectiveness with this examiner compared to others. Consider whether a continuation application might be more strategic, especially if you need to add new matter or significantly broaden claims.

After-Final Amendment Practice

This examiner enters after-final amendments leading to allowance in 19.0% of cases where such amendments are filed. This entry rate is in the 15% percentile among all examiners. Strategic Recommendation: This examiner rarely enters after-final amendments compared to other examiners. You should generally plan to file an RCE or appeal rather than relying on after-final amendment entry. Per MPEP § 714.12, primary examiners have discretion in entering after-final amendments, and this examiner exercises that discretion conservatively.

Pre-Appeal Conference Effectiveness

When applicants request a pre-appeal conference (PAC) with this examiner, 20.0% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 25% percentile among all examiners. Note: Pre-appeal conferences show limited success with this examiner compared to others. While still worth considering, be prepared to proceed with a full appeal brief if the PAC does not result in favorable action.

Appeal Withdrawal and Reconsideration

This examiner withdraws rejections or reopens prosecution in 45.5% of appeals filed. This is in the 8% percentile among all examiners. Of these withdrawals, 40.0% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner rarely withdraws rejections during the appeal process compared to other examiners. If you file an appeal, be prepared to fully prosecute it to a PTAB decision. Per MPEP § 1207, the examiner will prepare an Examiner's Answer maintaining the rejections.

Petition Practice

When applicants file petitions regarding this examiner's actions, 44.9% are granted (fully or in part). This grant rate is in the 49% percentile among all examiners. Strategic Note: Petitions show below-average success regarding this examiner's actions. Ensure you have a strong procedural basis before filing.

Examiner Cooperation and Flexibility

Examiner's Amendments: This examiner makes examiner's amendments in 0.0% of allowed cases (in the 0% percentile). This examiner rarely makes examiner's amendments compared to other examiners. You should expect to make all necessary claim amendments yourself through formal amendment practice.

Quayle Actions: This examiner issues Ex Parte Quayle actions in 0.0% of allowed cases (in the 0% percentile). This examiner rarely issues Quayle actions compared to other examiners. Allowances typically come directly without a separate action for formal matters.

Prosecution Strategy Recommendations

Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:

  • Prepare for rigorous examination: With a below-average allowance rate, ensure your application has strong written description and enablement support. Consider filing a continuation if you need to add new matter.
  • Expect multiple rounds of prosecution: This examiner issues more office actions than average. Address potential issues proactively in your initial response and consider requesting an interview early in prosecution.
  • Prioritize examiner interviews: Interviews are highly effective with this examiner. Request an interview after the first office action to clarify issues and potentially expedite allowance.
  • Plan for RCE after final rejection: This examiner rarely enters after-final amendments. Budget for an RCE in your prosecution strategy if you receive a final rejection.
  • Plan for extended prosecution: Applications take longer than average with this examiner. Factor this into your continuation strategy and client communications.

Relevant MPEP Sections for Prosecution Strategy

  • MPEP § 713.10: Examiner interviews - available before Notice of Allowance or transfer to PTAB
  • MPEP § 714.12: After-final amendments - may be entered "under justifiable circumstances"
  • MPEP § 1002.02(c): Petitionable matters to Technology Center Director
  • MPEP § 1004: Actions requiring primary examiner signature (allowances, final rejections, examiner's answers)
  • MPEP § 1207.01: Appeal conferences - mandatory for all appeals
  • MPEP § 1214.07: Reopening prosecution after appeal

Important Disclaimer

Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.

No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.

Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.

Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.